Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 6 (June)

1. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
   J Mass Spectrom, 43(6): 736-52. [Abstract] [Full-text]
2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
   Invest Ophthalmol Vis Sci, 49(6): 2348-56. [Abstract] [Full-text]
3. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
   Invest Ophthalmol Vis Sci, 49(6): 2337-42. [Abstract] [Full-text]
4. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol.
   FASEB J, 22(6): 1894-904. [Abstract] [Full-text]
5. Induced Disorder in Protein-Ligand Complexes as a Drug-Design Strategy.
   Mol Pharm, 5(3): 430-437. [Abstract] [Full-text]
6. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
   Oncogene. [Abstract] [Full-text]
7. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
   Ann Surg, 247(6): 1011-8. [Abstract] [Full-text]
8. Current status of therapy for chronic myeloid leukemia: a review of drug development.
   Future Oncol, 4(3): 359-77. [Abstract] [Full-text]
9. The current status and evolving role of sunitinib in non-small cell lung cancer.
   J Thorac Oncol, 3(6): S119-23. [Abstract] [Full-text]
10. A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature.
    World J Surg Oncol, 6: 50. [Abstract] [Full-text]
11. A multidisciplinary approach for the treatment of GIST liver metastasis.
    World J Surg Oncol, 6: 46. [Abstract] [Full-text]
12. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
    Curr Opin Oncol, 20(4): 433-7. [Abstract] [Full-text]
13. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.
    Curr Opin Oncol, 20(4): 428-32. [Abstract] [Full-text]
14. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Anticancer Drugs, 19(6): 607-12. [Abstract] [Full-text]
15. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Expert Rev Anticancer Ther, 8(6): 853-64. [Abstract] [Full-text]
16. Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
    Med Mycol, 46(3): 259-63. [Abstract] [Full-text]
17. Mathematical models of cancer stem cells.
    J Clin Oncol, 26(17): 2854-61. [Abstract] [Full-text]
18. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
    Br J Haematol. [Abstract] [Full-text]
19. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
    Leukemia, 22(6): 1184-90. [Abstract] [Full-text]
20. The effects of imatinib on pregnancy outcome.
    Blood, 111(12): 5505-8. [Abstract] [Full-text]
21. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
    Leukemia, 22(6): 1117-24. [Abstract] [Full-text]
22. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Leukemia, 22(6): 1200-6. [Abstract] [Full-text]
23. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
    Leukemia, 22(6): 1131-8. [Abstract] [Full-text]
24. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
    Leukemia, 22(6): 1191-9. [Abstract] [Full-text]
25. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
    Leuk Res, 32(10): 1620-2. [Abstract] [Full-text]
26. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
    Leuk Res, 32(10): 1608-10. [Abstract] [Full-text]
27. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
    Expert Opin Investig Drugs, 17(7): 1127-36. [Abstract] [Full-text]
28. Therapeutic options for patients with clonal and idiopathic hypereosinophia.
    Expert Opin Investig Drugs, 17(7): 1039-50. [Abstract] [Full-text]
29. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Cardiovasc Res, 79(1): 118-26. [Abstract] [Full-text]
30. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Int J Clin Oncol, 13(3): 244-51. [Abstract] [Full-text]
31. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges.
    Expert Opin Ther Targets, 12(7): 883-903. [Abstract] [Full-text]
32. Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.
    Int J Hematol. [Abstract] [Full-text]
33. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
    Clin Cancer Res, 14(12): 3906-15. [Abstract] [Full-text]
34. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Clin Cancer Res, 14(12): 3881-8. [Abstract] [Full-text]
35. Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases.
    Bioconjug Chem, 19(6): 1164-9. [Abstract] [Full-text]
36. Bcr-Abl induces autocrine IGF-1 signaling.
    Oncogene, 27(27): 3831-44. [Abstract] [Full-text]
37. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Oncology, 73(5): 324-7. [Abstract] [Full-text]
38. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Proc Natl Acad Sci U S A, 105(24): 8387-92. [Abstract] [Full-text]
39. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
    Am J Respir Crit Care Med, 178(1): 81-8. [Abstract] [Full-text]
40. Metabolism and disposition of dasatinib after oral administration to humans.
    Drug Metab Dispos, 36(7): 1357-64. [Abstract] [Full-text]
41. Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
    PLoS Comput Biol, 4(6): e1000095. [Abstract] [Full-text]
42. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
    J Biol Chem, 283(26): 18292-302. [Abstract] [Full-text]
43. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    J Surg Oncol, 98(1): 27-33. [Abstract] [Full-text]
44. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
    Int J Cancer, 123(4): 793-800. [Abstract] [Full-text]
45. Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
    Leuk Lymphoma, 49(6): 1168-77. [Abstract] [Full-text]
46. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
    Proteomics, 8(12): 2394-406. [Abstract] [Full-text]
47. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
    Blood, 112(1): 53-5. [Abstract] [Full-text]
48. Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.
    Ann Oncol, 19(7): 1320-6. [Abstract] [Full-text]
49. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Clin Nucl Med, 33(7): 486-7. [Abstract] [Full-text]
50. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
    J Clin Pathol, 61(7): 863-5. [Abstract] [Full-text]

© 2004-2010 Glivec Research Today. All Rights Reserved.